TEVA: En "big leagues" de salarios CEO (Kare Schultz)

.

Chairman Sol Barer, though, told investors repeatedly during Teva's months-long CEO search that the company wasn't messing around and would do whatever it took to nail down a "world-class" pick. It also relaxed a requirement that its CEO live in Israel, which has limited its options in the past.

Kare Schultz&Yitzhak Peterburg

The bulk of Schultz’s compensation came in stock awards which totaled $14.23 million. Option awards tallied $2 million, while his base salary checked in at $333,333. That base salary figure is more than $1 million less than Vigodman netted in each of the last three years, but it’s no surprise, considering Schultz’s task hinges on elevating Teva’s battered shares.

Teva also awarded Schultz $464,591 in other compensation, $125,000 of which went to reimbursing him for legal fees he incurred while negotiating his employment contract with Teva. A tax gross-up accounted for $201,339, while housing and relocation expenses reached $41,393.


Unfortunately for Teva, the company also forked over millions in 2017 to exiting employees. Besides Vigodman, who exited one month and change into 2017, former CFO Eyal Desheh; and former specialty meds CEO Rob Koremans each pocketed more than $1 million in termination payments. Overall, Vigodman made $2.83 million despite stepping down in February, while Desheh, who stepped down in July, grabbed $4.2 million.

Meanwhile, Novo Nordisk and Lundbeck veteran Schultz wasted no time cutting other costs at the Petah Tikva-based pharma. After taking the helm Nov. 1, he rolled out a $3 billion cost-squeezing plan in mid-December that’s set to claim 14,000 jobs when all is said and done.(Ver)

Ver:
Teva tiene un nuevo CEO…